Evommune reprices director David E. Cohen’s options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evommune, Inc. director David E. Cohen reported a one-time repricing of two outstanding options on November 13, 2026. The 37,960-share option with a $16.00 exercise price and the 15,673-share option with a $19.82 exercise price were each deemed canceled and replaced by an option covering the same share count at $7.63 per share. If he exercises an option before the earlier of November 13, 2027 and a Change in Control during Continuous Service, he must pay a premium exercise price equal to that option’s original exercise price. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to buy) F1, F2, F3 | 37,960 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F1, F2, F3 | 37,960 | -- | -- |
| Disposition | Stock Option (Right to buy) F4, F2, F5 | 15,673 | -- | -- |
| Grant/Award | Stock Option (Right to buy) F4, F2, F5 | 15,673 | -- | -- |
Footnotes (5)
- F1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 5, 2025 and is partially vested.
- F2. The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; and (ii) a Change in Control during the Reporting Person's Continuous Service, each as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
- F3. One third (1/3) of the shares subject to the option award vested on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- F4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 2, 2026.
- F5. The shares subject to the option award shall vest at the earlier of (i) June 2, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Key Terms
Option Repricing technical
Continuous Service technical
deemed cancellation technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options did Evommune (EVMN) director David E. Cohen reprice?
When do David E. Cohen’s replacement options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.